Experimental drug Brentuximab Vedotin (SGN-35) achieved tumor volume reductions in 94% of Relapsed or Refractory Hodgkin Lymphoma patients while 34% of them achieved complete remission, Seattle Genetics reported after completing a Pivotal Clinical Trial. The company expects to submit the...
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy. The study met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a...
Virco BVBA has announced that their HIV resistance testing product, virco®TYPE HIV-1, has achieved CE-Marking approval. virco®TYPE HIV-1 is the only bioinformatic diagnostic device of its kind to carry CE-Marking in the HIV market. The CE-Marking indicates that virco®TYPE HIV-1 is a medical...
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an...
Every year thousand of families are created with the assistance of in-vitro fertilization. Many of those newborns are twins. While some may see this as a double blessing, it is important to understand that there are many potential risks associated with multiple gestation. Statistics show that a...
Every year thousand of families are created with the assistance of in-vitro fertilization. Many of those newborns are twins. While some may see this as a double blessing, it is important to understand that there are many potential risks associated with multiple gestation. Statistics show that a...
Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppr
Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R)...
Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppr
Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R)...
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has achieved its protocol specified objective of enrolling 100 late-stage patients (Stage IIB to IVA) in its pivotal study for forodesine in the treatment of cutaneous T-cell lymphoma (CTCL). Top-line data is expected in the second...
Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA). In recent months, the last patient was enrolled in the CONFIRM trial, the second of two Phase III...